{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:50:11Z","timestamp":1793407811527,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cct.2026.108437","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:31:57Z","timestamp":1786750317000},"page":"108437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale"],"prefix":"10.1016","volume":"169","author":[{"given":"T. John","family":"Winhusen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Lofwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankie","family":"Kropp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Otterstatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Fanucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Vena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udi E.","family":"Ghitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2026.108437_bb0005","series-title":"As US overdose deaths drop, researchers search for explanations","author":"Anderer","year":"2026"},{"issue":"3","key":"10.1016\/j.cct.2026.108437_bb0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cct.2026.108437_bb0015","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.cct.2026.108437_bb0020","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.cct.2026.108437_bb0025","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2026.108437_bb0030","author":"National Quality Forum (NQF)"},{"issue":"5","key":"10.1016\/j.cct.2026.108437_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: a systematic review","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cct.2026.108437_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108764","article-title":"Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort","volume":"225","author":"Morgan","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.cct.2026.108437_bb0045","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.cct.2026.108437_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2026.0057","article-title":"Extended-release vs sublingual buprenorphine in pregnancy through 12 months post partum: a randomized clinical trial","author":"Winhusen","year":"2026","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.cct.2026.108437_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2026.108437_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109609","article-title":"Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder","volume":"239","author":"Rudolph","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2026.108437_bb0065","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/10550887.2016.1139427","article-title":"Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program","volume":"35","author":"Campbell","year":"2016","journal-title":"J. Addict. Dis."},{"issue":"4","key":"10.1016\/j.cct.2026.108437_bb0070","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/00952990.2023.2220876","article-title":"Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder","volume":"49","author":"Bhatraju","year":"2023","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.cct.2026.108437_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2022.107589","article-title":"Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: a systematic review of randomized controlled trials","volume":"139","author":"Baxley","year":"2023","journal-title":"Addict. Behav."},{"issue":"6","key":"10.1016\/j.cct.2026.108437_bb0080","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.cct.2026.108437_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2024.108023","article-title":"Mediating effect of craving on the impact of buprenorphine\/naloxone and methadone treatment on opioid use: results from a randomized controlled trial","volume":"154","author":"McAnulty","year":"2024","journal-title":"Addict. Behav."},{"key":"10.1016\/j.cct.2026.108437_bb0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","article-title":"Twin epidemics: the surging rise of methamphetamine use in chronic opioid users","volume":"193","author":"Ellis","year":"2018","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.cct.2026.108437_bb0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13722-023-00402-0","article-title":"The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review","volume":"18","author":"Russell","year":"2023","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.cct.2026.108437_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13722-021-00266-2","article-title":"The impact of methamphetamine\/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review","volume":"16","author":"Frost","year":"2021","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.cct.2026.108437_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2024.104434","article-title":"Prevalence of comorbid substance use disorders among people with opioid use disorder: a systematic review & meta-analysis","volume":"128","author":"Santo","year":"2024","journal-title":"Int. J. Drug Policy"},{"issue":"1","key":"10.1016\/j.cct.2026.108437_bb0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ajad.70075","article-title":"Exploring clinical profile and treatment outcome differences based on baseline smoking and alcohol co-use status among individuals initiating medication for opioid use disorder treatment","volume":"35","author":"Le\u00f3n","year":"2026","journal-title":"Am. J. Addict."},{"issue":"6","key":"10.1016\/j.cct.2026.108437_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304461","article-title":"Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder","volume":"19","author":"White","year":"2024","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cct.2026.108437_bb0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.sleep.2019.06.012","article-title":"Opioids and sleep\u2013a review of literature","volume":"67","author":"Tripathi","year":"2020","journal-title":"Sleep Med."},{"key":"10.1016\/j.cct.2026.108437_bb0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.addbeh.2017.07.016","article-title":"Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients","volume":"76","author":"Dunn","year":"2018","journal-title":"Addict. Behav."},{"issue":"1","key":"10.1016\/j.cct.2026.108437_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.462","article-title":"Glucagon-like peptide agonists: a prospective review","volume":"7","author":"Mariam","year":"2024","journal-title":"Endocrinol. Diabetes Metab."},{"key":"10.1016\/j.cct.2026.108437_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2026.03.1002","article-title":"GLP-1 receptor agonists in psychiatry: a pharmacoepidemiological scoping review","author":"Volkow","year":"2026","journal-title":"Biol. Psychiatry"},{"issue":"13","key":"10.1016\/j.cct.2026.108437_bb0140","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep Apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2026.108437_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleep.2025.106719","article-title":"Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity","volume":"134","author":"Kanu","year":"2025","journal-title":"Sleep Med."},{"issue":"1","key":"10.1016\/j.cct.2026.108437_bb0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/2229-3485.106383","article-title":"Placebo in clinical trials","volume":"4","author":"Gupta","year":"2013","journal-title":"Perspect. Clin. Res."},{"issue":"6","key":"10.1016\/j.cct.2026.108437_bb0155","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4103\/ijem.ijem_423_21","article-title":"Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: a cochrane meta-analysis","volume":"25","author":"Dutta","year":"2021","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.cct.2026.108437_bb0160","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.cct.2026.108437_bb0165","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/add.16626","article-title":"GLP-1R agonist medications for addiction treatment","volume":"120","author":"Volkow","year":"2024","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.cct.2026.108437_bb0170","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/ijnp\/pyaa034","article-title":"Treatment response of add-on esketamine nasal spray in resistant major depression in relation to add-on second-generation antipsychotic treatment","volume":"23","author":"Dold","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.cct.2026.108437_bb0175","first-page":"e114","volume":"152","author":"Members","year":"2025","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.cct.2026.108437_bb0180","doi-asserted-by":"crossref","DOI":"10.1111\/obr.70049","article-title":"GLP-1 receptor agonist medications for obesity and type 2 diabetes treatment: a rapid review of changes in eating behaviors and eating disorder risk","volume":"27","author":"Jebeile","year":"2025","journal-title":"Obes. Rev."},{"key":"10.1016\/j.cct.2026.108437_bb0185","author":"Bajaj"},{"key":"10.1016\/j.cct.2026.108437_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol. Behav."},{"issue":"2","key":"10.1016\/j.cct.2026.108437_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats","volume":"27","author":"Douton","year":"2022","journal-title":"Addict. Biol."},{"key":"10.1016\/j.cct.2026.108437_bb0200","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue-and drug-induced heroin seeking in high drug-taking rats","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.cct.2026.108437_bb0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","article-title":"Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue-and drug-induced fentanyl seeking in rats","volume":"189","author":"Urbanik","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.cct.2026.108437_bb0210","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-086886","article-title":"Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study","volume":"392","author":"Cai","year":"2026","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.cct.2026.108437_bb0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cct.2026.108437_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171117","article-title":"The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice","volume":"171","author":"Pacini","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.cct.2026.108437_bb0225","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.brainresbull.2022.11.012","article-title":"Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats","volume":"192","author":"Fang","year":"2023","journal-title":"Brain Res. Bull."},{"issue":"6","key":"10.1016\/j.cct.2026.108437_bb0230","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0361-9230(84)90145-X","article-title":"Sleep deficits in diabetic rats: restoration following chronic intravenous or intracerebroventricular infusions of insulin","volume":"12","author":"Danguir","year":"1984","journal-title":"Brain Res. Bull."},{"issue":"1\u20132","key":"10.1016\/j.cct.2026.108437_bb0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0006-8993(84)90359-7","article-title":"Chronic intracerebroventricular infusion of insulin causes selective increase of slow wave sleep in rats","volume":"306","author":"Danguir","year":"1984","journal-title":"Brain Res."},{"key":"10.1016\/j.cct.2026.108437_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleep.2025.106560","article-title":"Intranasal insulin enhances postoperative sleep quality and delirium in middle-aged cardiac surgery patients: a randomized controlled trial","volume":"132","author":"Yang","year":"2025","journal-title":"Sleep Med."},{"key":"10.1016\/j.cct.2026.108437_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-015-0074-6","article-title":"An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes","volume":"15","author":"Gomez-Peralta","year":"2015","journal-title":"BMC Endocr. Disord."},{"issue":"6","key":"10.1016\/j.cct.2026.108437_bb0250","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids","volume":"17","author":"Weimer","year":"2023","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.cct.2026.108437_bb0255","unstructured":"National Institute on Drug Abuse Center for Clinical Trials Network. CTN-0100: optimizing retention, duration, and discontinuation strategies for opioid use disorder pharmacotherapy. [Internet] 2024 [cited 2024 August 20]; Available from: https:\/\/ctnlibrary.org\/protocol\/ctn0100\/."},{"key":"10.1016\/j.cct.2026.108437_bb0260","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2026.108437_bb0265","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2026.108437_bb0270","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/SAR.S38902","article-title":"The treatment effectiveness assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction","author":"Ling","year":"2012","journal-title":"Subst. Abus. Rehabil."},{"issue":"2","key":"10.1016\/j.cct.2026.108437_bb0275","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.cct.2026.108437_bb0280","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.cct.2026.108437_bb0285","series-title":"Review of patient health questionnaire\u20139 (PHQ-9)","author":"Blackwell","year":"2014"},{"key":"10.1016\/j.cct.2026.108437_bb0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1008841022998","article-title":"Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease","volume":"7","author":"Revicki","year":"1997","journal-title":"Qual. Life Res."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426002235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426002235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:39:56Z","timestamp":1789184396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714426002235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"alternative-id":["S1551714426002235"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2026.108437","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2026.108437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108437"}}